Iconiq Lab, a global initial coin offering (ICO) and token sale accelerator program based in Germany, will soon launch two new branches in the US and Asia, Patrick Lowry, CEO of Iconiq Lab, told ...

VANCOUVER, BRITISH COLUMBIA, Sep 29, 2010 (MARKETWIRE via COMTEX) -- iCo Therapeutics Inc. is pleased to announce that the Company's oral Amphotericin B program, "iCo-009", has been granted Orphan ...

Customer engagement program, Giftz, has launched the first ICO pre-sale on equity crowdfunding platform Crowdfunder. The network, which is currently under development, consists of a universal rewards ...

iCo Therapeutics Grants License Option for Bertilimumab (iCo-008) Systemic Uses to Immune Pharmaceuticals for US$33 Million Plus Royalties VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec. 8, 2010) - ...

VANCOUVER, BC / ACCESSWIRE / November 28, 2016 / iCo Therapeutics (ICO.V) (ICOTF) ("iCo" or "the Company") announces several developments related to its novel, patent protected formulation of generic ...

BitMEX co-founder Arthur Hayes predicts that successful Web3 projects will adopt a “points” program before conducting token generation events. Former BitMEX CEO and Maelstrom chief investment officer ...

iCo’s main focus is on advancing its lead program, iCo-007, into phase 2 trials for the treatment of a Diabetes-related eye disease. Immune Pharma is paying iCo an option fee that will be credited ...

iCo Therapeutics (TSX-V: ICO), today announced that on November 26, 2013, U.S. patent 8,592,382 was issued for the Oral Amphotericin B platform (Oral AmpB) providing protection around oral delivery of ...